http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0609702-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2006-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4445ead7cc643ec15b53439462913dc0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ffd155fe0520701b45ae824d60372b0 |
| publicationDate | 2010-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0609702-A2 |
| titleOfInvention | biomarkers for the efficacy of aliskiren as a hypertensive agent |
| abstract | BIOMARKERS FOR ALISKIREN'S EFFICACY AS A HYPERTENSIVE AGENT. The present invention relates to a retrospective pharmacogenetic analysis that was conducted in an attempt to evaluate the potential association between genetic variation and the outcome of a clinical study of the efficacy of aliskiren as an antihypertensive agent. Forty-five polymorphisms were examined in twelve genes of the renin-angiotensin-aldosterone system (RAS) or previously implicated in the regulation of blood pressure. Significant associations were seen between a polymorphism in the angiotensin converting enzyme (ACE) gene, two polymorphisms in the type 2 angiotensin II receptor gene (AGTR2), and clinical parameters of reduced systolic and diastolic blood pressure at rest. These effects were not found with irbesartan and placebo treatment, but were instead specific for aliskiren treatment. |
| priorityDate | 2005-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 217.